Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
20
07
2022
pubmed:
7
8
2022
medline:
7
8
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
Medication-related osteonecrosis of the jaw is a serious adverse event associated with bone-modifying agents, such as injectable bisphosphonate (zoledronic acid) and the anti-receptor activator of nuclear factor-κB ligand antibody (denosumab). This study aims to evaluate and compare the time-to-onset profile for medication-related osteonecrosis of the jaw associated with denosumab between treatment-naïve (naïve group) and pre-treatment with zoledronic acid (post-zoledronic acid group) patients using the Japanese Adverse Drug Event Report database. Medication-related osteonecrosis of the jaw was defined according to the Medical Dictionary for Regulatory Activities. The medication-related osteonecrosis of the jaw onset profiles were evaluated using the Weibull shape parameter and the log-rank test. The Japanese Adverse Drug Event Report database contains 632,409 reports published between April 2004 and March 2020. In the time-to-onset analysis, after extracting the combinations with complete information for the treatment start date and the medication-related osteonecrosis of the jaw onset date, 272 reports of the naïve group and 86 reports of the post-zoledronic acid group were analyzed. The median onset in the naïve and post-zoledronic acid groups was 487.0 (25-75%: 274.0-690.8) and 305.5 (25-75%: 158.3-508.5) days, respectively. Medication-related osteonecrosis of the jaw occurred earlier in the post-zoledronic acid group than in the naïve group, and the log-rank test demonstrated a significant difference in their time transitions (p < 0.0001). The results indicated a risk of medication-related osteonecrosis of the jaw in naïve and post-zoledronic acid groups and a shorter onset time in the latter than in the former. Thus, healthcare professionals should take the early risk of medication-related osteonecrosis of the jaw into account when switching patients from zoledronic acid to denosumab treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Medication-related osteonecrosis of the jaw is a serious adverse event associated with bone-modifying agents, such as injectable bisphosphonate (zoledronic acid) and the anti-receptor activator of nuclear factor-κB ligand antibody (denosumab).
OBJECTIVE
OBJECTIVE
This study aims to evaluate and compare the time-to-onset profile for medication-related osteonecrosis of the jaw associated with denosumab between treatment-naïve (naïve group) and pre-treatment with zoledronic acid (post-zoledronic acid group) patients using the Japanese Adverse Drug Event Report database.
METHODS
METHODS
Medication-related osteonecrosis of the jaw was defined according to the Medical Dictionary for Regulatory Activities. The medication-related osteonecrosis of the jaw onset profiles were evaluated using the Weibull shape parameter and the log-rank test.
RESULTS
RESULTS
The Japanese Adverse Drug Event Report database contains 632,409 reports published between April 2004 and March 2020. In the time-to-onset analysis, after extracting the combinations with complete information for the treatment start date and the medication-related osteonecrosis of the jaw onset date, 272 reports of the naïve group and 86 reports of the post-zoledronic acid group were analyzed. The median onset in the naïve and post-zoledronic acid groups was 487.0 (25-75%: 274.0-690.8) and 305.5 (25-75%: 158.3-508.5) days, respectively. Medication-related osteonecrosis of the jaw occurred earlier in the post-zoledronic acid group than in the naïve group, and the log-rank test demonstrated a significant difference in their time transitions (p < 0.0001).
CONCLUSIONS
CONCLUSIONS
The results indicated a risk of medication-related osteonecrosis of the jaw in naïve and post-zoledronic acid groups and a shorter onset time in the latter than in the former. Thus, healthcare professionals should take the early risk of medication-related osteonecrosis of the jaw into account when switching patients from zoledronic acid to denosumab treatment.
Identifiants
pubmed: 35933498
doi: 10.1007/s40801-022-00324-4
pii: 10.1007/s40801-022-00324-4
pmc: PMC9712889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
659-665Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K10408
Organisme : Japan Society for the Promotion of Science
ID : 21K06646
Informations de copyright
© 2022. The Author(s).
Références
Cancer Chemother Pharmacol. 2021 Jun;87(6):871-877
pubmed: 33791853
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
J Pharm Health Care Sci. 2017 Jul 19;3:19
pubmed: 28729910
Drug Saf. 2013 Oct;36(10):995-1006
pubmed: 23673816
J Bone Miner Res. 2016 Feb;31(2):336-40
pubmed: 26288087
Support Care Cancer. 2016 Jan;24(1):447-455
pubmed: 26335402
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):547-551
pubmed: 29574058
BMC Med Res Methodol. 2013 Jul 16;13:92
pubmed: 23855337
Ther Clin Risk Manag. 2018 Dec 24;15:59-64
pubmed: 30636879
Ann Oncol. 2012 May;23(5):1341-1347
pubmed: 21986094
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
pubmed: 17062708
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):3-10
pubmed: 11998548
J Oral Pathol Med. 2018 Jan;47(1):66-70
pubmed: 28977694
J Clin Oncol. 2019 Sep 1;37(25):2270-2290
pubmed: 31329513
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Med Oral Patol Oral Cir Bucal. 2020 May 1;25(3):e326-e336
pubmed: 32271321
J Clin Endocrinol Metab. 2005 Mar;90(3):1897-9
pubmed: 15758064
J Pharm Health Care Sci. 2015 Dec 22;1:34
pubmed: 26819745
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
J Clin Oncol. 2010 Dec 10;28(35):5132-9
pubmed: 21060033
J Bone Miner Metab. 2017 Jan;35(1):6-19
pubmed: 28035494
Pharmaceuticals (Basel). 2020 Dec 16;13(12):
pubmed: 33339150
Brief Bioinform. 2018 Sep 28;19(5):863-877
pubmed: 28334070
J Clin Oncol. 2011 Mar 20;29(9):1125-32
pubmed: 21343556
Cancer. 2021 Nov 01;127(21):4050-4058
pubmed: 34310704
Acta Clin Belg. 2018 Apr;73(2):100-109
pubmed: 28693379
Cancer Treat Rev. 2018 Sep;69:177-187
pubmed: 30055439
Stat Med. 2009 May 1;28(10):1498-511
pubmed: 19235263
J Am Dent Assoc. 2005 Dec;136(12):1658-68
pubmed: 16383047
Nat Rev Drug Discov. 2012 May;11(5):401-19
pubmed: 22543469
BMJ Open. 2017 Sep 11;7(9):e016022
pubmed: 28893744